Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments-Reference-Cited by-同舟云学术

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Published:2023-09 Issue: Volume:190 Page:112944
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Valenza Carmine^ORCID,Trapani Dario^ORCID,Gandini Sara^ORCID,Sposetti Caterina^ORCID,Boscolo Bielo Luca,Marra Antonio^ORCID,Giarratano Tommaso,Favero Diletta^ORCID,Cortesi Laura^ORCID,Moscetti Luca,Pistelli Mirco,Berardi Rossana,Zambelli Alberto,Lambertini Matteo^ORCID,Del Mastro Lucia,Guarneri Valentina^ORCID,Vernieri Claudio,Curigliano Giuseppe^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Breast cancer;Loibl;The Lancet,2021

2. Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation;Baert;Breast Cancer Res,2016

3. Synthetic lethality — a new direction in cancer-drug development;Iglehart;New Engl J Med,2009

4. Cancer susceptibility and the functions of BRCA1 and BRCA2;Venkitaraman;Cell,2002

5. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial;Tutt;Nat Med,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review;Cancer Treatment Reviews;2024-11

2. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

3. PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments;Current Opinion in Oncology;2024-08-23

4. Using Trastuzumab Deruxtecan to treat advanced metastatic breast cancer in patients with varying HER2 expression levels: A single-center experience in Taiwan;Medicine;2024-07-12